Apollomics Inc. (NASDAQ:APLM – Get Free Report) shares were up 51.3% on Friday . The stock traded as high as $20.98 and last traded at $18.43. Approximately 682,200 shares traded hands during trading, an increase of 751% from the average daily volume of 80,162 shares. The stock had previously closed at $12.18.
Apollomics Trading Up 51.3%
The firm’s 50-day simple moving average is $7.95 and its two-hundred day simple moving average is $6.97.
Apollomics Company Profile
Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.
See Also
- Five stocks we like better than Apollomics
- How to Capture the Benefits of Dividend Increases
- Pfizer is Locking in New Growth Through a New Acquisition
- How to Short Nasdaq: An Easy-to-Follow Guide
- Copper Giant Freeport Slumps but Analysts See 33% Upside
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- The BYD Opportunity: Tesla-Like Growth at a Fraction of the Price
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
